USANA Health Sciences Stock Forecast, Price & News

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, USNA shares have increased by 8.3% and is now trading at $75.65.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for USANA Health Sciences.

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for USANA Health Sciences.

USANA Health Sciences, Inc. (NYSE:USNA) posted its earnings results on Tuesday, October, 20th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.29 by $0.15. The business had revenue of $298.50 million for the quarter, compared to analyst estimates of $281.80 million. USANA Health Sciences had a return on equity of 32.87% and a net margin of 10.35%. The firm's revenue was up 14.5% on a year-over-year basis. During the same period last year, the company posted $1.09 earnings per share.
View USANA Health Sciences' earnings history.

USANA Health Sciences announced that its board has approved a stock buyback plan on Wednesday, February 5th 2020, which authorizes the company to repurchase $130,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 9.1% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its shares are undervalued.

USANA Health Sciences updated its FY20 earnings guidance on Tuesday, October, 20th. The company provided EPS guidance of $5.15-5.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.20. The company issued revenue guidance of $1.09-1.115 billion, compared to the consensus revenue estimate of $1.09 billion.

Some companies that are related to USANA Health Sciences include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Prestige Consumer Healthcare (PBH), Medifast (MED), Inter Parfums (IPAR), Revlon (REV), Nature's Sunshine Products (NATR) and Veru (VERU).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include International Business Machines (IBM), Gilead Sciences (GILD), NVIDIA (NVDA), AT&T (T), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), The Walt Disney (DIS), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Robeco Institutional Asset Management B.V. (0.29%), WINTON GROUP Ltd (0.26%), Empowered Funds LLC (0.18%), Assenagon Asset Management S.A. (0.12%), Empirical Finance LLC (0.07%) and Comerica Bank (0.06%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Robert Auciaux, Timothy E Wood and Walter Noot.
View institutional ownership trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Alberta Investment Management Corp, First Quadrant L P CA, Comerica Bank, State of Alaska Department of Revenue, and Dupont Capital Management Corp. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Timothy E Wood, and Walter Noot.
View insider buying and selling activity for USANA Health Sciences.

USNA stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Empirical Finance LLC, Empowered Funds LLC, KBC Group NV, Bowling Portfolio Management LLC, Louisiana State Employees Retirement System, BNP Paribas Arbitrage SA, and WINTON GROUP Ltd. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull, and Myron W Wentz.
View insider buying and selling activity for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $75.65.

USANA Health Sciences has a market capitalization of $1.59 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis. USANA Health Sciences employs 1,909 workers across the globe.

The official website for USANA Health Sciences is www.usana.com.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]